| Regulatory status | BUNDLE |
|---|---|
| Mechanism | Dual GIP/GLP-1 + amylin analogue (two-vial bundle) |
| Form | Two lyophilized vials · 10mg + 10mg, 30mg + 10mg, 60mg + 10mg |
| CAS | Investigational (bundle of two) |
| Purity docs | Batch-matched COA available on request — ask us. |
| Ships from | Ontario, Canada |
| Intended use | Laboratory research only. Not for human consumption. |
This bundle pairs tirzepatide, the dual GIP/GLP-1, with cagrilintide, the long-acting amylin analogue — three distinct satiety pathways in a single order. The amylin + incretin principle is established: in the phase 3 REDEFINE-1 trial, cagrilintide combined with semaglutide produced 22.7% mean weight loss at 68 weeks, and a preclinical study of this exact pairing (cagrilintide + tirzepatide) in obese rats showed greater weight loss than either compound alone. No published human trial has studied tirzepatide and cagrilintide together — this is a research combination, not a trial-validated one. Each bundle ships as two separate lyophilized vials — one tirzepatide at the selected strength, one cagrilintide 10 mg, never combined or premixed.
Lyophilized vials: keep sealed, dry, and away from light and heat. Refrigeration at 2–8°C is the best default; −20°C for long-term storage. After reconstitution: refrigerate at 2–8°C and use promptly — no beyond-use date is validated.
Three satiety pathways in one order. One tirzepatide vial + one cagrilintide 10 mg vial.
New here? Start here →
In stock — ships within 48 hours of payment.
$15 flat shipping Canada-wide · free over $200
The original once-weekly GLP-1 weight-loss medicine — the compound that started the class.
GLP-1 receptor agonist
The newer, stronger once-weekly weight-loss medicine — dual GIP/GLP-1 action in one molecule.
Dual GIP / GLP-1 receptor agonist
A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US.
Dual GLP-1 / glucagon receptor agonist
